Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer / 浙江大学学报·医学版
Journal of Zhejiang University. Medical sciences
;
(6): 395-402, 2016.
Artigo
em Chinês
| WPRIM
| ID: wpr-239573
ABSTRACT
Bevacizumab is increasingly used in recurrent, persistent or metastatic cervical cancer. The early retrospective case reports found that bevacizumab combined with 5-FU (including capecitabine) or paclitaxel was well tolerated and displayed encouraging anti-tumor activity in recurrent or persistent cervical cancer. Phase Ⅱ clinical trials showed that bevacizumab was well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer. Large scale phase Ⅱ and phase Ⅲ clinical trials demonstrated that bevacizumab-containing chemotherapy was effective in the first- and second-line treatment of patients with persistent cervical cancer, prolonged survival time and improved remission rate. The article also reviews the research progress on predictive factors of bevacizumab efficacy, showing the use of imaging and biomarkers in predicting the efficacy of bevacizumab treatment. In addition, this article analyzes the cost-effectiveness of bevacizumab, finding that bevacizumab combined with chemotherapy meets the standard of cost-effectiveness.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Indução de Remissão
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias do Colo do Útero
/
Taxa de Sobrevida
/
Estudos Retrospectivos
/
Mortalidade
/
Resultado do Tratamento
/
Custos de Cuidados de Saúde
/
Análise Custo-Benefício
/
Paclitaxel
Tipo de estudo:
Avaliação Econômica em Saúde
/
Estudo observacional
/
Estudo prognóstico
Limite:
Feminino
/
Humanos
Idioma:
Chinês
Revista:
Journal of Zhejiang University. Medical sciences
Ano de publicação:
2016
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS